Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 192

Sort by

Sort Order Select

Journal Articles

Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 5657.

https://doi.org/10.1182/blood-2025-5657

Published: 2025

Journal Articles

Loss of cell cycle regulators RB1 and CDKN2A/2B induces CLL with distinct disease kinetics in murine models and shows distinct outcomes in CLL patients

Ivan Negara, Nevenka Ridova, Federico Jauk, Esther Sathya Bama Benjamin, Marija Vujovikj, Claudio Martines, Giulia Felician, Nadica Matevska-Geshkovska, Davide Rossi, Luca Laurenti, Irina Panovska, Aleksandar Dimovski, Dimitar Efremov

Blood (2025) 146 (Supplement 1): 3879.

https://doi.org/10.1182/blood-2025-3879

Published: 2025

Journal Articles

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

Hyun Yong Jin, Jeff Sharman, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Paolo Sportoletti, Archie Egginton, Maria Thadani-Mulero, Oscar Cazarez, Yanwen Jiang, Michelle Boyer, Franck Morschhauser

Blood (2025) 146 (Supplement 1): 682.

https://doi.org/10.1182/blood-2025-682

Published: 2025

Journal Articles

PD-1 expression on richter syndrome tumor cells does not provide a growth advantage in murine or patient-derived xenograft models In Vivo

Ivan Negara, Esther Sathya Bama Benjamin, Giulia Felician, Claudio Martines, Marija Vujovikj, Tiziana Vaisitti, Silvia Deaglio, Aleksandar Dimovski, Luca Laurenti, Dimitar Efremov

Blood (2025) 146 (Supplement 1): 2104.

https://doi.org/10.1182/blood-2025-2104

Published: 2025

Journal Articles

A comprehensive geriatric assessment to evaluate individual frailty status and quality of life in patients with Waldenström macroglobulinemia: A prospective italian study

Blood (2025) 146 (Supplement 1): 5362.

https://doi.org/10.1182/blood-2025-5362

Published: 2025

Journal Articles

TP53 mutations in paired bone marrow and cell-free DNA samples of patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance prospectively enrolled in the FIL_biowm study of fondazione italiana linfomi

Blood (2025) 146 (Supplement 1): 5318.

https://doi.org/10.1182/blood-2025-5318

Published: 2025

Journal Articles

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Blood (2025) 146 (Supplement 1): 7427.

https://doi.org/10.1182/blood-2025-7427

Published: 2025

Journal Articles

Btkis and DRC show a reduction of infections and need of hospitalization towards BR and other chemo-immunotherapies in waldenstrom macroglobulinemia.

Blood (2025) 146 (Supplement 1): 1833.

https://doi.org/10.1182/blood-2025-1833

Published: 2025

Journal Articles

Very low risk for secondary malignancies with btkis in Waldenström macroglobulinemia: A retrospective real-world multicenter study.

Blood (2025) 146 (Supplement 1): 5390.

https://doi.org/10.1182/blood-2025-5390

Published: 2025

Journal Articles

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2025-3301

Published: 2025

Journal Articles

Oncogeriatric assessment of patients with chronic lymphatic leukaemia over 65 years old undergoing target therapies: A pilot study conducted at the fondazione policlinico gemelli.

Idanna Innocenti, Giuseppe Ferdinando Colloca, Luca Stirparo, Annamaria Tomasso, Tommaso Quaranta, Antonio Mosca, Francesco Iadevaia, Feliciana Guglielmi, Andrea Bellieni, Francesco Landi, Giulia Giordano, Francesco Autore, Alberto Fresa, Dimitar Efremov, Luca Laurenti

Blood (2025) 146 (Supplement 1): 7412.

https://doi.org/10.1182/blood-2025-7412

Published: 2025

Journal Articles

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfo, Persefoni Talimtzi, Maria Angelopoulou, Tomas Arpas, Laura Ballotta, Leonidas Benetatos, Ana Margarida Bertolo, Horia Bumbea, Maurizio Cavallari, Anastasia Chatzidimitriou, Dominik Chraniuk, Anna Christoforidou, Francesca Cibien, Antonio Cuneo, Maria Ilaria del Principe, Marina Deodato, Enrico Derenzini, Michael Doubek, Fabiana Esposito, Lucia Farina, Gianmarco Favrin, Isacco Ferrarini, Annamaria Frustaci, Andrea Galitzia, Massimo Gentile, Iulia Roxana Iancu, Vanessa Innao, krzysztof jamroziak, Elzbieta Kalicinska, Maria Kislova, Ioannis Kyriakou, Luca Laurenti, Enrico Lista, Javier Loscertales, Alexandros Machairas, Giorgia Marcato, Francesca Martini, Nilla Maschio, Eva Minga, Riccardo Moia, Roberta Murru, Maura Nicolosi, Jacopo Olivieri, Carolina Pavlovsky, Miguel Pavlovsky, Sara Pepe, Ernesto Perez Persona, Giuseppe Petruzzellis, Gian Matteo Rigolin, Alessandro Sanna, Marina Siakantaris, Paolo Sportoletti, Oana Stanca, Niki Stavrogianni, Tamar Tadmor, Annamaria Tomasso, Marzia Varettoni, Theodoros Vassilakopoulos, Eva Gimeno Vazquez, Candida Vitale, Mohamed Yassin, Mihnea Zdrenghea, Klaudia Zielonka, Livio Trentin, Kostas Stamatopoulos, Paolo Ghia

Blood (2025) 146 (Supplement 1): 6287.

https://doi.org/10.1182/blood-2025-6287

Published: 2025

Journal Articles

Longitudinal analysis of richter syndrome risk and survival in CLL: The role of targeted therapy and molecular markers. experience at the fondazione policlinico gemelli in rome.

Idanna Innocenti, Tommaso Quaranta, Francesco Iadevaia, Annamaria Tomasso, Luca Stirparo, Antonio Mosca, Alberto Fresa, Giulia Benintende, Florenzia Vuono, Feliciana Guglielmi, Pier Luigi Abbate, Arianna Bakacs, Dimitar Efremov, Eugenio Sangiorgi, Francesco Autore, Luca Laurenti

Blood (2025) 146 (Supplement 1): 5679.

https://doi.org/10.1182/blood-2025-5679

Published: 2025

Journal Articles

Chronic obstructive pulmonary disease and prior pneumonia as predictors of infectious risk in chronic lymphocytic leukemia patients receiving acalabrutinib or zanubrutinib: A seifem multicentre Study.

Blood (2025) 146 (Supplement 1): 5678.

https://doi.org/10.1182/blood-2025-5678

Published: 2025

Journal Articles

Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.

Blood (2025) 146 (Supplement 1): 5671.

https://doi.org/10.1182/blood-2025-5671

Published: 2025

Journal Articles

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.

Thomas Chatzikonstantinou, Persefoni Talimtzi, Eva Minga, Maria Angelopoulou, Miguel Arguello De Tomas, Darko Antic, Celso Arrais-Rodrigues, Francesc Bosch Albareda, Marcello Bradaschia, Alessandro Cellini, Mark Catherwood, Sophia Chatzileontiadou, Caterina Chessa, Carlos Chiattone, Rosa Collado, Marta Coscia, Marta Crespo, Antonio Cuneo, Zadie Davis, Maria Dimou, Michael Doubek, Maria Efstathopoulou, Blanca Espinet, Gianluca Gaidano, Rocio Garcia-Serra, Alessandro Gozzetti, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Ozren Jaksic, Maria Kislova, Eliana Konstantinou, Sevasti Konstantinou, Maya Koren Michowitz, Ioannis Kotsianidis, Andreas Epameinondas Koumpis, Luca Laurenti, Alexandros Machairas, Francesca Martini, Riccardo Moia, Samir Mouhssine, Ana Muntanola Prat, Roberta Murru, Rocio Nieves Salgado Sanchez, Gerassimos Pangalis, Maria Papaioannou, Sarka Pavlova, Leila Perobelli, Sarka Pospisilova, Anna Puiggros, Claus Rainer, Sergio Ramos, Lata Rani, Gian Matteo Rigolin, Ilaria Romano, Davide Rossi, Rodrigo Santucci, Angel Serna, Marina Siakantaris, Talita Silveira, Paolo Sportoletti, Niki Stavrogianni, Annamaria Tomasso, Kristina Tomic Vujovic, Livio Trentin, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Munci Yagci, Seyma Yildiz, Anastasia Chatzidimitriou, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2025) 146 (Supplement 1): 5664.

https://doi.org/10.1182/blood-2025-5664

Published: 2025

Journal Articles

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

Blood (2025) 146 (11): 1300–1313.

https://doi.org/10.1182/blood.2024027877

Published: 2025

Includes: Supplemental data

Journal Articles

Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience

Blood (2024) 144 (Supplement 1): 6798.

https://doi.org/10.1182/blood-2024-203557

Published: 2024

Journal Articles

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Enrica Antonia Martino, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Andrea Visentin, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Annamaria Frustaci, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Gerardo Musuraca, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Ernesto Vigna, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Ludovico Fraticelli, Candida Vitale, Azzurra Anna Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozzella, Luigi Malandruccolo, Enrico Derenzini, Valentina di Martina, Roberto Marasca, Maria Ilaria Del Principe, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Antonino Neri, Pellegrino Musto, Francesco Di Raimondo, Alessandra Tedeschi, Livio Trentin, Gianluca Gaidano, Fortunato Morabito, Valter Gattei, Massimo Gentile

Blood (2024) 144 (Supplement 1): 6794.

https://doi.org/10.1182/blood-2024-205354

Published: 2024

Journal Articles

Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study

Blood (2024) 144 (Supplement 1): 3013.

https://doi.org/10.1182/blood-2024-200111

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia

Loss of cell cycle regulators RB1 and CDKN2A/2B induces CLL with distinct disease kinetics in murine models and shows distinct outcomes in CLL patients

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

PD-1 expression on richter syndrome tumor cells does not provide a growth advantage in murine or patient-derived xenograft models In Vivo

A comprehensive geriatric assessment to evaluate individual frailty status and quality of life in patients with Waldenström macroglobulinemia: A prospective italian study

TP53 mutations in paired bone marrow and cell-free DNA samples of patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance prospectively enrolled in the FIL_biowm study of fondazione italiana linfomi

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Btkis and DRC show a reduction of infections and need of hospitalization towards BR and other chemo-immunotherapies in waldenstrom macroglobulinemia.

Very low risk for secondary malignancies with btkis in Waldenström macroglobulinemia: A retrospective real-world multicenter study.

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Oncogeriatric assessment of patients with chronic lymphatic leukaemia over 65 years old undergoing target therapies: A pilot study conducted at the fondazione policlinico gemelli.

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Longitudinal analysis of richter syndrome risk and survival in CLL: The role of targeted therapy and molecular markers. experience at the fondazione policlinico gemelli in rome.

Chronic obstructive pulmonary disease and prior pneumonia as predictors of infectious risk in chronic lymphocytic leukemia patients receiving acalabrutinib or zanubrutinib: A seifem multicentre Study.

Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only